| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
N-Acetyl-D-galactosamine-6-phosphate is a substrate involved in galactose metabolism and the phosphotransferase system (PTS). It can be hydrolyzed by NagA. It has been shown to inhibit the haemagglutinating activity of Alectin II, a compound isolated from aloe vera leaf pulp. It participates as a substrate in the sugar metabolism pathway and regulates cell wall synthesis and hydrolysis metabolism.
|
|---|---|
| ln Vitro |
In vitro, N-Acetyl-D-galactosamine-6-phosphate is involved in galactose metabolism and the phosphotransferase system (PTS). It is used as a substrate in enzymatic activity assays to study carbohydrate metabolism and the regulation of sugar phosphate pathways.
|
| ln Vivo |
In vivo, N-Acetyl-D-galactosamine-6-phosphate is involved in galactose metabolism and the phosphotransferase system (PTS). It may be used in metabolic studies to investigate sugar phosphate pathways.
|
| Enzyme Assay |
In vitro enzyme assays for N-Acetyl-D-galactosamine-6-phosphate involve studying its role as a substrate in galactose metabolism and the phosphotransferase system (PTS). Enzymatic activity assays can be performed to measure its hydrolysis by NagA.
|
| Cell Assay |
In vitro cellular assays for N-Acetyl-D-galactosamine-6-phosphate are performed using cell lines to study carbohydrate metabolism and the regulation of sugar phosphate pathways. Cells are treated with the compound, and metabolic flux is analyzed.
|
| Animal Protocol |
In vivo animal studies with N-Acetyl-D-galactosamine-6-phosphate would typically be conducted in models of metabolic disorders to study carbohydrate metabolism and sugar phosphate pathways.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of N-Acetyl-D-galactosamine-6-phosphate are not applicable, as it is a biochemical reagent rather than a drug. The compound is not intended for administration as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
The toxicity profile of N-Acetyl-D-galactosamine-6-phosphate is not extensively reported. As a biochemical reagent, it is not intended for human therapeutic use. No specific toxicity data are detailed.
|
| Additional Infomation |
N-acetyl-D-glucosamine-6-phosphate is an N-acetyl derivative of D-glucosamine-6-phosphate, belonging to the N-acyl-D-glucosamine-6-phosphate family. It is a component of amino sugar metabolism and has metabolites in Escherichia coli, Saccharomyces cerevisiae, humans, and mice. Its function is related to D-glucosamine. It is the conjugate acid of N-acetyl-D-glucosamine-6-phosphate (2-). N-acetyl-D-glucosamine-6-phosphate is present in or produced by Escherichia coli (K12 strain, MG1655 strain). N-acetyl-D-glucosamine-6-phosphate has been reported in humans and Trypanosoma brevicornu, with relevant data. N-acetyl-D-glucosamine-6-phosphate is present in or produced by Saccharomyces cerevisiae. See also: N-acetyl-D-glucosamine-6-phosphate (note moved to).
N-Acetyl-D-galactosamine-6-phosphate (CAS 18191-20-3) is a galactosamine phosphate involved in galactose metabolism and the phosphotransferase system (PTS). It has a molecular formula of C8H16NO9P and a molecular weight of 301.19. The compound is used as a biochemical tool in studies of carbohydrate metabolism and enzymatic activity assays. It is available for research purposes only. |
| Molecular Formula |
C8H16NO9P
|
|---|---|
| Molecular Weight |
301.188
|
| Exact Mass |
301.056
|
| CAS # |
18191-20-3
|
| PubChem CID |
440996
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-4.2
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
371
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(=O)NC1C(C(C(OC1O)COP(=O)(O)O)O)O
|
| InChi Key |
BRGMHAYQAZFZDJ-RTRLPJTCSA-N
|
| InChi Code |
InChI=1S/C8H16NO9P/c1-3(10)9-5-7(12)6(11)4(18-8(5)13)2-17-19(14,15)16/h4-8,11-13H,2H2,1H3,(H,9,10)(H2,14,15,16)/t4-,5-,6-,7-,8?/m1/s1
|
| Chemical Name |
[(2R,3S,4R,5R)-5-acetamido-3,4,6-trihydroxyoxan-2-yl]methyl dihydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3202 mL | 16.6008 mL | 33.2016 mL | |
| 5 mM | 0.6640 mL | 3.3202 mL | 6.6403 mL | |
| 10 mM | 0.3320 mL | 1.6601 mL | 3.3202 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
